UroLift is a minimally invasive office procedure used to treat benign prostatic hyperplasia (BPH), otherwise known as enlarged prostate. In most cases, it eliminates the need for oral medications and risks that are associated with more invasive surgeries. The UroLift System treatment has demonstrated a significant improvement in quality of life for patients compared to medications. The UroLift System is the only BPH procedure shown not to cause new and lasting erectile or ejaculatory dysfunction, while being a safe and effective treatment of lower urinary tract symptoms due to BPH.
Frequently Asked Questions
The UroLift Implants are small permanent implants that hold the obstructing prostatic lobes apart. They are deployed through a needle that comes out of the delivery device. Each implant is made with common implantable materials: nitinol, stainless steel, and suture. Typically, 4-6 implants are placed into the prostate.
The examination performed will be determined by your physician. The physician will likely ask you to fill out a questionnaire to assess your symptoms, otherwise known as IPSS (International Prostate Symptom Score). Additionally, some of the common examinations include Digital Rectal Exam (DRE), Transrectal Ultrasonography (TRUS), Bladder Ultrasound, Cystoscopy, and Urinalysis.
If you and your doctor decide that the UroLift System treatment is right for you, your doctor will provide you with more detailed information relating to the treatment. In general, the UroLift System is a minimally invasive treatment that entails minimal downtime. Your doctor will use the UroLift Delivery Device to deploy permanent implants to relieve obstruction caused by the enlarged prostate that is pressing on your urethra.
The procedure, which usually takes less than an hour, may be performed under local or general anesthesia and you may be given medication to feel comfortable during the treatment. This typically helps minimize discomfort during the procedure, though everyone’s definition for pain and discomfort varies greatly. Typically, no catheter and no overnight stay is required post-treatment.
After the treatment, patients typically go home the same day without a catheter. There is minimal downtime post-treatment and many patients experience symptom relief in as early as 2 weeks. Patients may experience some urinary discomfort during the recovery period. The most common side effects may include blood in the urine, some pain or discomfort when urinating, some increased urge to go and discomfort in the pelvis that typically resolve within two to four weeks after the procedure.
The implant is made up of standard surgical implantable materials: a nitinol tab, a stainless-steel tab, and polyester suture that holds the two tabs together. Your doctor can remove the urethral implant, if needed.
Clinical studies have shown the UroLift System treatment does not cause new, sustained instances of erectile or ejaculatory dysfunction. The same cannot always be said of other BPH therapies such as TURP, laser, and even medication.
Non-clinical testing has demonstrated that the UroLift Implant is MR Conditional. A patient with this device can be safely scanned in an MR system immediately after placement meeting the following conditions:
- Static magnetic field of 3.0 Tesla or less
- Maximum spatial field gradient of 1,500 Gauss/cm (15 T/m) (extrapolated)
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4 W/kg for 15 minutes of continuous scanning (i.e., per pulse sequence) (First Level Controlled Operating Mode)
Under the scan conditions defined above, the UroLift Implant is expected to produce a maximum temperature rise of 2.4°C after 15 minutes of continuous scanning (i.e., per pulse sequence)
In non-clinical testing, the image artifact caused by the device extends approximately 15 mm from the UroLift Implant when imaged with a gradient echo pulse sequence and a 3.0 Tesla MRI system.
The safety of the delivery system has not been evaluated in the MR environment, and therefore, the delivery system should not be used within the MR environment.
Patient implant cards are provided to inform the patient that the UroLift implant is MR Conditional and can safely be scanned only under specific MR conditions.
If you have any questions about MRI safety, please consult your doctor.
The implants are not expected to interfere with a DRE. The implants are placed on the anterior (front) side of the prostate, and a DRE is conducted on the posterior (back) side of the prostate.
In our clinical studies, the most common side effects reported were mild to moderate and include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge. Most symptoms resolved within two to four weeks after the procedure.
"This is a highly professional Office that provide excellent care to makes me comfortable to visit each time when I needed."
"I am very satisfied with my treatment at Foothill Urogenital. All the staff are courteous and caring. Thanks for responding to my needs and prompt scheduling."
"I arrived early, and was taken right in. My doctor spent a lot of time with me discussing options - not seemingly in a hurry. I felt comforted my concerns were answered"
"The visit was easier than I expected but also very professional."
"Great practice. Ben and Dr. Y give the best level of service. They both take the time to make the patient at ease."
"To me trust, education, and experience are the 3 things I look for in any medical practitioner. Dr. Yamada has all three."
"Dr. Yamada was wonderful. He made sure we understood the procedures [and that] the necessary pre-op procedures were scheduled."
"Outstanding. As a result of his diligence in evaluating my condition the doctors were able to identify and treat in time a second life-threatening health issue."